THE PSYCHEDELIC AND KETAMINE RENAISSANCE IN THE FACE OF THE CRISIS IN MODERN PSYCHIATRY
Authors:
- Julia OsipowskaJOJulia Osipowska
- Marlena KwolekMKMarlena Kwolek
- Alicja JudzińskaAJAlicja Judzińska
- Bartosz PiechBPBartosz Piech
- Kamila SobczyńskaKSKamila Sobczyńska
- Justyna IgnarskaJIJustyna Ignarska
- Magda TerboshMTMagda Terbosh
- Sabina Kubicz-MzabiSKSabina Kubicz-Mzabi
- Emilia TrojanowskaETEmilia Trojanowska
- Magdalena DubajMDMagdalena Dubaj
Open Access
- 26 May 2026
- journal article
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 2 (2(50))
Abstract
Introduction: Contemporary psychiatry is grappling with a profound stagnation in innovation. It is primarily relying on the chronic management of symptoms through traditional daily-dose pharmacotherapy. The emergence of psychedelics and ketamine marks a significant departure from this model. It is offering rapid-acting, interventional alternatives that target the underlying neurobiological mechanisms of mental disorders rather than mere symptom suppression. Purpose: The primary objective of this article is to evaluate the therapeutic potential of psychedelics and ketamine as catalysts for a new paradigm in mental healthcare. The paper aims to synthesize current knowledge on 5-HT2A receptor agonism, the development of next-generation non-hallucinogenic psychoplastogens, and the ethical-legal challenges associated with implementing these treatments in the global and Polish healthcare systems. Methodology: This study employs a multidisciplinary literature review, integrating recent findings from neuropsychopharmacology, clinical trial outcomes, and bioethical analysis. It compares the efficacy and administration models of classic psychedelics against conventional treatments (e.g., SSRIs) and examines the socioeconomic factors influencing the democratization of these therapies. Conclusions: The "psychedelic renaissance" necessitates the adoption of a new language for psychiatry, rooted in neuroplasticity and connectivity. To achieve widespread scalability, the field must focus on isolating the plasticity effect and utilizing short-acting tryptamines to reduce clinical resource burdens. Furthermore, for Poland to actively participate in this medical revolution, urgent legislative harmonization and robust ethical frameworks regarding patient suggestibility are required.Keywords
This publication has 71 references indexed in Scilit:
- The Economic Burden of Adults with Major Depressive Disorder in the United States (2019)Advances in Therapy, 2023
- Brain-Derived Neurotrophic Factor Signaling in Depression and Antidepressant ActionBiological Psychiatry, 2021
- Errors in a Response Rate and in Effect Sizes in Study of Psilocybin-Assisted Therapy for Major Depressive DisorderJAMA Psychiatry, 2021
- A single inhalation of vapor from dried toad secretion containing 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) in a naturalistic setting is related to sustained enhancement of satisfaction with life, mindfulness-related capacities, and a decrement of psychopathological symptomsPsychopharmacology, 2019
- Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant DepressionJAMA Psychiatry, 2018
- Psilocybin with psychological support for treatment-resistant depression: six-month follow-upPsychopharmacology, 2017
- A Consensus Statement on the Use of Ketamine in the Treatment of Mood DisordersJAMA Psychiatry, 2017
- Depressive Rumination, the Default-Mode Network, and the Dark Matter of Clinical NeuroscienceBiological Psychiatry, 2015
- A Neurotrophic Model for Stress-Related Mood DisordersBiological Psychiatry, 2006
- A selective inhibitor of serotonin uptake: Lilly 110140, 3-(p-Trifluoromethylphenoxy)-n-methyl-3-phenylpropylamineLife Sciences, 1974